Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLPTNASDAQ:PAVMNASDAQ:RCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$6.80+1.2%$7.02$4.05▼$10.95$183.44M0.89157,155 shs84,050 shsPAVMPAVmed$2.14-21.6%$2.25$1.60▼$9.36$19.62M0.8872,685 shs193,249 shsRCELAVITA Medical$16.03-2.8%$16.83$9.16▼$21.70$412.13M1.39167,014 shs126,171 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+1.19%-0.29%-13.49%+0.15%-17.87%PAVMPAVmed-21.61%+0.94%-6.55%-48.06%-59.81%RCELAVITA Medical-2.85%-0.62%-12.45%+16.84%+18.04%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLPTClearPoint Neuro1.3118 of 5 stars3.51.00.00.03.20.00.6PAVMPAVmed3.6157 of 5 stars3.03.00.04.32.90.80.0RCELAVITA Medical1.8161 of 5 stars3.53.00.00.02.70.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro3.00Buy$12.0076.47% UpsidePAVMPAVmed2.00Hold$21.00881.31% UpsideRCELAVITA Medical3.00Buy$27.8073.42% UpsideCurrent Analyst RatingsLatest PAVM, CLPT, and RCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $9.002/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.001/19/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $22.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$23.96M7.66N/AN/A$0.86 per share7.91PAVMPAVmed$2.45M8.01N/AN/A$1.36 per share1.57RCELAVITA Medical$50.14M8.22N/AN/A$1.92 per share8.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$22.09M-$0.91N/AN/AN/A-92.21%-83.94%-47.92%5/9/2024 (Estimated)PAVMPAVmed-$88.98M-$9.33N/A∞N/A-2,617.25%-532.56%-85.99%5/21/2024 (Estimated)RCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/9/2024 (Estimated)Latest PAVM, CLPT, and RCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint Neuro0.474.873.80PAVMPAVmedN/A0.450.60RCELAVITA Medical0.817.887.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%PAVMPAVmed19.93%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro4.94%PAVMPAVmed12.60%RCELAVITA Medical1.96%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro10726.98 million25.42 millionOptionablePAVMPAVmed1249.17 million7.04 millionOptionableRCELAVITA Medical20725.71 million25.20 millionOptionablePAVM, CLPT, and RCEL HeadlinesSourceHeadlineRCEL Apr 2024 22.500 putfinance.yahoo.com - March 16 at 8:16 AMRCEL Oct 2024 17.500 putfinance.yahoo.com - March 16 at 8:16 AMAVITA Medical: Unconvincing Growth Amid Fierce Competition In The Burn Care Sectorseekingalpha.com - March 5 at 2:05 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementfinance.yahoo.com - February 29 at 4:15 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementglobenewswire.com - February 29 at 4:02 PMAVITA Medical to Present at TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 29 at 9:00 AMFY2024 EPS Estimates for AVITA Medical, Inc. (NASDAQ:RCEL) Cut by Cantor Fitzgeraldmarketbeat.com - February 29 at 8:41 AMAVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69nasdaq.com - February 26 at 10:49 PMBRIEF-Seatrium Limited Says FY Revenue S$7.3 Blnsg.finance.yahoo.com - February 26 at 1:49 AMAvita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Ratingmarkets.businessinsider.com - February 23 at 5:44 PMAVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 12:43 PMAVITA Medical to Host Investor Webinar Briefingglobenewswire.com - February 23 at 9:01 AMArdelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionmsn.com - February 23 at 7:35 AMBuy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategymarkets.businessinsider.com - February 23 at 2:34 AMAVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidanceglobenewswire.com - February 22 at 4:01 PMAVITA Medical Q4 2023 Earnings Previewmsn.com - February 21 at 2:21 PMRCEL Mar 2024 15.000 callfinance.yahoo.com - February 17 at 12:44 PMAVITA Medical, Inc. (NASDAQ:RCEL): Are Analysts Optimistic?finance.yahoo.com - February 7 at 3:22 PMAVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 1 at 7:40 PMAvita Medical Poised for Growth: Buy Rating and $40 Price Target Justified by Strategic Partnerships and Positive Financial Indicatorsmarkets.businessinsider.com - January 12 at 12:45 AMAVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientificfinance.yahoo.com - January 10 at 6:49 PMAVITA Medical Inc (RCEL) rating initates by Cantor Fitzgeraldknoxdaily.com - January 1 at 2:07 PMAVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentumseekingalpha.com - December 19 at 11:15 PMAvita Medical cuts 2023 commercial revenue guidance on longer hospital approval timelinesmsn.com - November 20 at 11:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsClearPoint NeuroNASDAQ:CLPTClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.PAVmedNASDAQ:PAVMPAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.